Merus N.V.
39.00
-1.45 (-3.58%)
At close: Jan 14, 2025, 3:59 PM
39.01
0.01%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 38
Market Cap 2.67B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -3.72
PE Ratio (ttm) -10.48
Forward PE n/a
Analyst Buy
Ask 40.67
Volume 1,008,817
Avg. Volume (20D) 560,991
Open 40.62
Previous Close 40.45
Day's Range 38.63 - 40.62
52-Week Range 31.27 - 61.61
Beta undefined

About MRUS

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also de...

Industry Biotechnology
Sector Healthcare
IPO Date May 19, 2016
Employees 172
Stock Exchange NASDAQ
Ticker Symbol MRUS

Analyst Forecast

According to 11 analyst ratings, the average rating for MRUS stock is "Buy." The 12-month stock price forecast is $85, which is an increase of 117.95% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Merus N.V. is scheduled to release its earnings on Feb 26, 2025, during market hours.
Analysts project revenue of $8.95M, reflecting a 0.12% YoY growth and earnings per share of -0.94, making a -13.76% decrease YoY.
1 day ago · Source
-7.75%
Merus shares are trading lower. The company announ... Unlock content with Pro Subscription
1 month ago · Source
+8.23%
Merus shares are trading higher after the company announced it entered into an agreement to exclusively license the right to Ptx the right to commercialize Zenocutuzumab (Zeno) for Nrg1 Fusion-positive cancer in the US.